Military Medical Academy

At the Military Medical Academy in Pleven, the Department of Neurological Diseases is active in studies focused on nervous system diseases and immune system processes, with a strong emphasis on multiple sclerosis, Parkinson’s disease, and epilepsy. These trials are designed to better understand disease control, support symptom management, and evaluate new treatment options for long-term neurological care.

• Research in multiple sclerosis includes relapsing and progressive forms, with trials aimed at reducing relapses and slowing disability progression.
• Parkinson’s disease studies are exploring the safety and tolerability of treatments intended to support ongoing disease management.
• Epilepsy research is examining therapies for difficult-to-control seizures to improve seizure reduction and patient stability.

Overall, the site contributes to clinical research that seeks to improve treatment effectiveness and long-term outcomes in complex neurological conditions.

The site has a major research presence in autoimmune diseases and immune-mediated inflammatory disorders, especially systemic lupus erythematosus, cutaneous lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis. These studies are generally aimed at testing new therapies, improving disease control, and assessing whether treatments can reduce inflammation and improve daily functioning.

• Systemic lupus erythematosus and cutaneous lupus erythematosus trials are focused on reducing disease activity and skin involvement.
• Sjögren’s syndrome research is examining ways to ease systemic symptoms and patient-reported discomfort.
• Rheumatoid arthritis studies are evaluating treatment effectiveness in patients with inadequate response to standard care.

This research area highlights the site’s role in advancing options for chronic inflammatory conditions that often require long-term specialist care.

Clinical trials at the Military Medical Academy also cover a wide range of skin diseases, including atopic dermatitis, psoriasis, hidradenitis suppurativa, and vitiligo. The main purpose of these studies is to test new approaches that may improve skin symptoms, reduce flare-ups, and support better quality of life for people with persistent dermatologic disease.

• Atopic dermatitis and psoriasis trials are evaluating treatments for moderate to severe disease activity.
• Hidradenitis suppurativa research is focused on symptom relief and longer-term disease control.
• Vitiligo studies are examining whether new therapies can improve repigmentation and disease management.

These studies reflect an active effort to expand treatment choices in chronic inflammatory skin disorders.

Another important research area involves respiratory tract diseases and allergic conditions, including asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis, and allergic rhinoconjunctivitis. The trials in this field are mainly designed to evaluate treatment effectiveness, improve control of symptoms, and reduce exacerbations in both chronic and severe disease.

• Asthma studies include moderate, severe, and eosinophilic forms, with a focus on better symptom control.
• Chronic obstructive pulmonary disease research is assessing therapies that may improve breathing and lung function.
• Chronic rhinosinusitis and allergic rhinoconjunctivitis trials are exploring ways to relieve persistent upper-airway symptoms.

This portfolio shows a strong interest in improving care for common and burdensome respiratory and allergy-related illnesses.

Trials in cardiovascular diseases at this site include research on atrial fibrillation, coronary artery disease, heart failure, and prevention of ischemic stroke. These studies are intended to evaluate new ways to reduce serious complications, improve protection against clot-related events, and support safer long-term management of cardiovascular risk.

• Atrial fibrillation studies are assessing strategies to lower stroke risk in patients who cannot use standard anticoagulation.
• Ischemic stroke prevention research is focused on reducing recurrence after a recent event or high-risk transient ischemic attack.
• Heart failure and broader cardiovascular studies aim to improve outcomes in patients with chronic heart disease.

These trials underline the site’s contribution to safer, more effective prevention strategies in high-risk cardiovascular populations.

The site also participates in studies of virus diseases and bacterial infections, with notable work in chronic hepatitis B, tuberculosis, COVID-19, and complicated urinary tract infection. In parallel, some trials address liver disease and treatment safety in people with hepatic impairment, reflecting a broad interest in infection control and organ-specific care.

• Chronic hepatitis B studies are examining whether new treatments can improve long-term viral control and move toward functional cure.
• Tuberculosis and COVID-19 research is focused on treatment support in serious infectious illness.
• Complicated urinary tract infection trials are evaluating whether new antibiotic approaches can improve clinical and microbiological response.

These studies show an ongoing effort to strengthen treatment options for both common and high-impact infectious diseases.

Clinical research at this hospital/clinic also spans metabolic diseases, hemic and lymphatic diseases, and neoplasms. Key areas include severe hypertriglyceridemia, gout, myelofibrosis, myelodysplastic syndromes, and selected cancers. These studies are generally intended to test new therapies, compare treatment effectiveness, and improve disease control in complex chronic conditions.

• Severe hypertriglyceridemia and gout studies are evaluating better ways to manage metabolic risk and uric acid levels.
• Myelofibrosis and myelodysplastic syndromes research is focused on improving outcomes in blood disorders.
• Neoplasm trials include work in selected solid tumors, aiming to assess whether new cancer treatments can improve survival.

Overall, the site’s research portfolio reflects broad clinical activity across chronic metabolic, hematologic, and oncology-related disease areas.